08 Monoclonal Antibody Facility

08 单克隆抗体设施

• 批准号: 10212256
• 负责人: Laura del Carmen Bover
• 金额: $ 19.8万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-08-28 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10212256
• 关键词: Affinity; Antibodies; Antibody Affinity; Antigen Targeting; Antigens; Avidity; Biotechnology; Cancer Biology; Cancer Center; Cancer Center Support Grant; Capital; Cells; Clinical; Consultations; Crystallography; Custom; Diagnosis; Equipment; Funding; Future; Generations; Goals; Grant; Hand; Human Resources; Image; Immunoglobulin Variable Region; Immunohistochemistry; Immunotherapy; In Vitro; Journals; Legal patent; Light; Mission; Monoclonal Antibodies; Names; OX40; Outcome; Pathologic; Peer Review; Peptides; Pharmacologic Substance; Phase I Clinical Trials; Price; Proteins; Publications; Research; Research Personnel; Research Support; Role; Science; Scientist; Services; System; Technology; Therapeutic Uses; Time; Training; assay development; cancer immunotherapy; clinical development; diagnostic assay; experience; hybridoma production; improved; insight; interest; member; new technology; pre-clinical; programs; screening; tool

PROJECT SUMMARY: MONOCLONAL ANTIBODY FACILITY (MAF) The importance of immunotherapy research to advancing the field of cancer biology and improving clinical outcomes has surged in recent years, prompting Science magazine to name cancer immunotherapy its 2013 Breakthrough of the Year. Recognition of the power of immunotherapy has heightened interest in and demand for rapid, affordable monoclonal antibody (MAb) services, and improved technologies are needed to provide cutting-edge, high-quality molecules required for today's science. The Monoclonal Antibody Facility (MAF) at MD Anderson is actively participating in this endeavor. The mission of the MAF is to produce de novo MAbs against newly discovered or existing antigens, and to purify unique high-quality custom MAbs in a timely and effective manner, with the value added of scientific advice and competitive prices. Dr. Laura Bover has directed the MAF since 2007, and in 2016 hired a senior research scientist, Dr. Roberto Rangel, who is bringing additional new technologies to the core. The number of MAbs produced in grant Yr42 has tripled when compared with the average of the previous grant period (48 in Yr42 and 16 on average for the previous grant period). Four MAF- generated MAbs have been licensed to pharmaceutical companies for clinical development, and additional MAbs have been licensed to biotechnology companies for in vitro use. In addition, the MAb anti-OX40, generated in 2012, has progressed to a phase I clinical trial. In the past 6-year period, the MAF has supported the research of 72 MD Anderson center members, representing all 16 CCSG programs, in contrast to 40 investigators in the previous grant period. MD Anderson has provided an additional $717,769 in capital equipment funds. MD Anderson members with peer-reviewed funding accounted for 90% of the usage, and 35% ($128,415) support is requested from the CCSG in Yr44. MAF supported 57 publications, with 35 publications (61%) in journals with an IF of >5 and 10 publications (18%) in journals with an IF of >10. The MAF Specific Aims are: 1) To produce, in a timely, effective manner at competitive prices, unique high-affinity, high-quality custom MAbs that are suitable for diverse applications that meet the cancer center users' requirements. 2) To provide consultation and assistance, including: a) selection and generation of appropriate antigen formats (peptides, proteins, or cells expressing the target); b) troubleshooting any antigen- or screening-related issues; c) characterization of the produced antibodies (PK, affinity, avidity, and competition); d) assay development for the particular applications and users' goals, including imaging, immunohistochemistry, diagnostic assays, crystallography, and preclinical and future therapeutic use; e) advice for IND filing and patent requirements; f) training and assistance on the subsequent screening (in users' hands) of the positive candidates selected by the MAF for the particular desired application.

项目摘要：单克隆抗体设施 (MAF) 免疫治疗研究对于推进癌症生物学领域和改善临床的重要性 近年来，结果激增，促使《科学》杂志将癌症免疫疗法定为 2013 年年度报告 年度突破。对免疫疗法力量的认识提高了人们对免疫疗法的兴趣和需求 需要快速、负担得起的单克隆抗体 (MAb) 服务，并且需要改进的技术来提供 当今科学所需的尖端、高质量分子。 MD 的单克隆抗体设施 (MAF) 安德森正在积极参与这一努力。 MAF 的使命是从头生产针对 新发现的或现有的抗原，并及时有效地纯化独特的高质量定制单克隆抗体 方式，并提供科学建议和有竞争力的价格的附加值。 Laura Bover 博士指导 MAF 自 2007 年以来，并于 2016 年聘请了一位高级研究科学家 Roberto Rangel 博士，他带来了更多新的 技术到核心。与第 42 年拨款相比，第 42 年拨款中产生的单克隆抗体数量增加了两倍 上一个补助期的平均值（42 年为 48，上一个补助期平均为 16）。四个 MAF- 生成的单克隆抗体已授权给制药公司进行临床开发，并且其他单克隆抗体 已授权给生物技术公司用于体外使用。此外，MAb 抗 OX40 产生于 2012年，已进展至I期临床试验。在过去的6年里，MAF支持了这项研究 MD 安德森中心有 72 名成员，代表所有 16 个 CCSG 项目，而 MD 安德森中心有 40 名研究人员 之前的资助期。 MD Anderson 额外提供了 717,769 美元的资本设备资金。医学博士 拥有同行评审资金的安德森成员占使用量的 90%，并获得 35%（128,415 美元）的支持 第 44 年向 CCSG 提出请求。 MAF 支持了 57 篇出版物，其中 35 篇出版物 (61%) 发表在以下期刊上： IF > 5 和 10 篇出版物 (18%) 在 IF > 10 的期刊上。 MAF 的具体目标是： 1) 生产、 以具有竞争力的价格及时、有效地提供独特的高亲和力、高质量的定制单克隆抗体 适用于满足癌症中心用户需求的多种应用。 2）提供咨询和 协助，包括： a) 选择和生成适当的抗原形式（肽、蛋白质或细胞） 表达目标）； b) 解决任何抗原或筛选相关问题； c) 表征 产生的抗体（PK、亲和力、亲合力和竞争）； d) 针对特定应用的分析开发 和用户的目标，包括成像、免疫组织化学、诊断分析、晶体学和临床前 以及未来的治疗用途； e) IND 申请和专利要求的建议； f) 培训和协助 随后筛选（在用户手中）MAF 为特定所需目的选择的阳性候选者 应用。